APC anti-mouse IFN-γ Antibody

Catalog# / Size	505809 / 25 µg 505810 / 100 µg
Clone	XMG1.2
Regulatory Status	RUO
Other Names	Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype	Rat IgG1, κ
Description	IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	*E. coli*-expressed, recombinant mouse IFN-γ
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. **Do not freeze.**
Application	ICFC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Red Laser (633 nm)
Application Notes	**ELISA[1-4,11,14] or ELISPOT[5] Detection:** The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard. **ELISA or ELISPOT Capture:** The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). **Flow Cytometry[7,8,12,13,16]:** The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-?-producing cells within mixed cell populations. **Neutralization[1-3,9,10]:** The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-?. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-? bioactivity *in vivo* and *in vitro* (Cat. No. 505812). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg). **Additional reported applications (for the relevant formats) include:** Western blotting, immunohistochemical staining of frozen tissue sections[6,22,23], and immunocytochemistry. **Note:** For testing mouse IFN-? in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets

(Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

1. Abrams J, *et al.* 1992. *Immunol. Rev.* 127:5. (ELISA, Neut)
2. Sander B, *et al.* 1993. *J. Immunol. Meth.* 166:201. (ELISA, Neut)
3. Abrams J, *et al.* 1995. *Curr. Prot. Immunol.* John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
4. Yang X, *et al.* 1993. *J. Immunoassay* 14:129. (ELISA)
5. Klinman D, *et al.* 1994. *Curr. Prot. Immunol.* John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
6. Sander B, *et al.* 1991. *Immunol. Rev.* 119:65. (IHC)
7. Ferrick D, *et al.* 1995. *Nature* 373:255. (FC)
8. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309. (FC) PubMed
9. Peterson KE, *et al.* 2000. *J. Virol.* 74:5363. (Neut)
10. DeKrey GK, *et al.* 1998. *Infect. Immun.* 66:827. (Neut)
11. Dzhagalov I, *et al.* 2007. *J. Immunol.* 178:2113. (ELISA)
12. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366. (FC)
13. Lee JW, *et al.* 2006. *Nature Immunol.* 8:181. (FC) PubMed
14. Xu G, *et al.* 2007. *J. Immunol.* 179:5358. (ELISA) PubMed
15. Montfort M, *et al.*2004. *J. Immunol.* 173:4084. PubMed
16. Haring JS, *et al.* 2008. *J. Immunol.* 180:2855. (FC) PubMed
17. Jordan JM, *et al.* 2008. *Infect Immun.* 76:3717. PubMed
18. Tonkin DR, *et al.* 2008. *J. Immunol.* 181:4516. PubMed
19. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) PubMed
20. Cui Y, *et al.* 2009. *Invest. Ophth. Vis. Sci.* 50:5811. (FC) PubMed
21. Mykkanen OT, *et al.* 2014. *PLoS One.* 9:114790. PubMed
22. Yokogawa M, *et al.* 2013. *Mol. Carcinog.* 52:760. (IHC)
23. Mottram PL, *et al.* 1998. *J Immunol.* 161:602. (IHC)

Product Citations

1. Nenasheva T, *et al.* 2017. PLoS One. 12(6):e0178983. PubMed
2. Bankoti R, *et al.* 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
3. Ding Z, *et al.* 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
4. Vacca M, *et al.* 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
5. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
6. Fatkhullina AR *et al.* 2018. Immunity. 49(5):943-957 . PubMed
7. Aurélien Trompette *et al.* 2018. Immunity. 48(5):992-1005 . PubMed
8. Cignarella F *et al.* 2018. Cell metabolism. 27(6):1222-1235 . PubMed
9. Liu Y, *et al.* 2018. Cancer Cell. 33:480. PubMed
10. Logan K Smith *et al.* 2018. Immunity. 48(2):299-312 . PubMed
11. Malik A *et al.* 2018. Immunity. 49(3):515-530 . PubMed
12. Lu Y, *et al.* 2018. Cancer Cell. 33:1048. PubMed
13. Ogawa C *et al.* 2018. Cell reports. 25(1):19-28 . PubMed
14. Fujita Y *et al.* 2018. Cell reports. 24(12):3296-3311 . PubMed
15. Snell LM, *et al.* 2018. Immunity. 49:678. PubMed
16. Dietmar Herndler-Brandstetter *et al.* 2018. Immunity. 48(4):716-729 . PubMed
17. Chinta KC *et al.* 2018. Cell reports. 25(7):1938-1952 . PubMed
18. Cao W, *et al.* 2017. Immunity. 47:1182. PubMed
19. Kang YH, *et al.* 2019. Nat Commun. 10:912. PubMed
20. van Vloten JP, *et al.* 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
21. Lu J, *et al.* 2018. ACS Nano. 12:11041. PubMed
22. Huang F, *et al.* 2018. Oncoimmunology. 7:e1450713. PubMed
23. Sinclair LV *et al.* 2019. Elife. 8 pii: e44210. PubMed
24. Qi X, *et al.* 2019. Nat Commun. 10:2141. PubMed
25. Yang S, *et al.* 2019. Nat Commun. 10:2782. PubMed
26. Luo Y *et al.* 2019. Cell reports. 26(7):1869-1879 . PubMed
27. Kwak JE, *et al.* 2019. Nat Commun. 10:3836. PubMed
28. Niemann J, *et al.* 2019. Nat Commun. 10:3236. PubMed
29. Yang C, *et al.* 2018. J Immunol. 200:1316. PubMed
30. Saleh MM, *et al.* 2019. Cell Host Microbe. 25:756. PubMed
31. Komuczki J, *et al.* 2019. Immunity. 50:1289. PubMed
32. Chow MT *et al.* 2019. Immunity. 50(6):1498-1512 . PubMed
33. Samarchith P Kurup *et al.* 2019. Cell host & microbe. 25(4):565-577 . PubMed
34. Liu D *et al.* 2019. Immunity. 51(1):64-76 . PubMed
35. Sparber F, *et al.* 2019. Cell Host Microbe. 25:389. PubMed
36. Park JY, *et al.* 2019. Cell Rep. 27:2548. PubMed
37. van Montfoort N, *et al.* 2018. Cell. 175:1744. PubMed
38. Oliveira AC *et al.* 2017. eLife. 6 pii: e30883. PubMed
39. Ying Zhang *et al.* 2017. Cancer cell. 32(3):377-391 . PubMed
40. Xie A *et al.* 2017. Endocrinology. 158(10):3140-3151 . PubMed
41. Qi S *et al.* 2016. eLife. 5 pii: e14756. PubMed
42. Deng Z, *et al.* 2017. Oncogene. 36:639. PubMed
43. Matsuoka S, *et al.* 2019. Haematologica. 105:226. PubMed
44. Wong YC, *et al.* 2019. J Virol. 93:e01154-19. PubMed
45. Zheng X, *et al.* 2019. PLoS Pathog. 15:e1008036. PubMed
46. Ron–Harel N, *et al.* 2019. Cell Rep. 28:3011. PubMed
47. Levesque S, *et al.* 2019. Oncoimmunology. 8:e1657375. PubMed
48. Kim C, *et al.* 2019. Cell Rep. 29:2202. PubMed
49. Angiari S, *et al.* 2020. Cell Metab. 31:391. PubMed
50. Dokoshi T, *et al.* 2020. Cell Rep. 30:61. PubMed

51. Rosenbaum SR, *et al.* 2020. Cell Rep. 30:510. PubMed
52. Saini V, *et al.* 2020. Nat Commun. 0.845138889. PubMed
53. Zhang D, *et al.* 2020. Signal Transduct Target Ther. 5:24. PubMed
54. Maluski M, *et al.* 2019. J Clin Invest. 129:5108. PubMed
55. Chaurasiya S, *et al.* 2020. Oncoimmunology. 9:1729300. PubMed
56. Li Y, *et al.* 2020. Cell Rep. 30:1753. PubMed
57. Ouyang S, *et al.* 2019. J Immunol. 202:1441. PubMed
58. Burrack AL, *et al.* 2019. Cell Rep. 28:2140. PubMed
59. Renner K, *et al.* 2020. Cell Reports. 29(1):135-150.e9.. PubMed
60. Gorman JA, *et al.* 2019. Front Immunol. 10:44. PubMed
61. Kisielow J, *et al.* 2019. Nat Immunol. 1.286111111. PubMed
62. Dudeck J, *et al.* 2019. J Allergy Clin Immunol. 143:1849. PubMed
63. Cella M, *et al.* 2019. Nat Immunol. 1.513888889. PubMed
64. Muri J, *et al.* 2020. Cell Reports. 30(13):4399-4417. PubMed
65. Hudson WH, *et al.* 2020. Immunity. 51(6):1043-1058.e4.. PubMed
66. Pham THM, *et al.* 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
67. Dong MB, *et al.* 2020. Cell. 178(5):1189-1204.e23.. PubMed
68. Muri J, *et al.* 2020. eLife. 9:e53627.. PubMed
69. Steinmann S, *et al.* 2020. Sci Rep. 1.160416667. PubMed
70. Liang J, *et al.* 2020. Sci Adv. 6:eabc3646. PubMed
71. Montfort M, *et al.* 2004. J Immunol. 173:4084. PubMed
72. Tonkin D, *et al.* 2008. J Immunol. 181:4516. PubMed
73. Jin R, *et al.* 2008. J Immunol. 180:2256. PubMed
74. Lai C, *et al.* 2009. Invest Ophthalmol Vis Sci. 50:4279. PubMed
75. Harty J 2009. Infect Immun. 77:1894. PubMed
76. Lee J, *et al.* 2007. Nat Immunol. 8:181. PubMed
77. Murakami R, *et al.* 2013. PLoS One. 8:73270. PubMed
78. DeBerge M, *et al.* 2013. PLoS One. 8:79340. PubMed
79. Byrne K, *et al.* 2014. J Immunol. 192:1433. PubMed
80. Hartwig S, *et al.* 2014. PLoS One. 9:90720. PubMed
81. Bhattacharya D, *et al.* 2014. J Biol Chem. 289:16508. PubMed
82. El-Zaatari M, *et al.* 2014. J Immunol. 193:807. PubMed
83. Nagaoka M, *et al.* 2014. J Immunol. 193:2812. PubMed
84. Lu X, *et al.* 2015. J Immunol. 194:2011. PubMed
85. Cabrera-Perez C, *et al.* 2015. J Immunol . 194:1609-20. PubMed
86. Zhao Y, *et al.* 2015. PLoS One. 10: 0134797. PubMed
87. Muthumani K, *et al.* 2015. Sci Transl Med. 7: 301ra132. PubMed
88. Flesch I, *et al.* 2015. J Immunol. 195: 2263-2272. PubMed
89. Cabrera-Mora M, *et al.* 2015. Infect Immun . 83: 3749-3761. PubMed
90. Vijay R, *et al.* 2015. J Exp Med. 212: 1851 - 1868. PubMed
91. Kurihara T, *et al.* 2015. PLoS One. 10: e0139692. PubMed
92. Yu H, *et al.* 2015. PLoS One. 10: 0143001. PubMed
93. Bransi A, *et al.* 2015. Cancer Immunol Res. 3: 1279 - 1288. PubMed
94. Chen S, *et al.* 2015. Cancer Res . 7: 519-531. PubMed
95. Montes de Oca M, *et al.* 2016. PLoS Pathog. 12: 1005398. PubMed
96. Uddback I, *et al.* 2016. Sci Rep. 6:20137. PubMed
97. Jackson C, *et al.* 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
98. Du C, *et al.* 2016. Nat Commun. 7: 11120. PubMed
99. Domeier P, *et al.* 2016. J Exp Med. 213: 715 - 732. PubMed
100. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
101. Chou T, *et al.* 2016. Nat Commun. 7:11904. PubMed
102. M H, *et al.* 2016. Open Bio. 6: 150208. PubMed
103. Mingozzi F, *et al.* 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
104. Hilpert C, *et al.* 2016. J Immunol. 197: 2780 - 2786. PubMed
105. Quispe Calla N, *et al.* 2016. Sci Rep. 6:37723. PubMed
106. Laroche-Lefebvre C, *et al.* 2016. J Immunol. 197: 3618 - 3627. PubMed
107. Knocke S, *et al.* 2016. Cell Rep. 17:2234-2246. PubMed
108. Dekhtiarenko I, *et al.* 2016. PLoS Pathog. 12:e1006072. PubMed
109. Li M, *et al.* 2020. J Immunother Cancer. 8:00. PubMed
110. Harsha Krovi S, *et al.* 2020. Nat Commun. 4.790277778. PubMed
111. Sanchez-Felipe L, *et al.* 2021. Nature. 590:320. PubMed
112. Len-Letelier RA, *et al.* 2020. Frontiers in Immunology. 11:583382. PubMed
113. Ma X, *et al.* 2020. Immunity. 53:1315. PubMed
114. Moon J, *et al.* 2020. Immune Netw. 20:e40. PubMed
115. Fang Y, *et al.* 2021. J Clin Invest. 131:00:00. PubMed
116. Faust HJ, *et al.* 2020. J Clin Invest. 130:5493. PubMed
117. Varikuti S, *et al.* 2020. Br J Cancer. 122:1005. PubMed
118. Wang H, *et al.* 2020. Nat Mater. 1.655555556. PubMed
119. Zhang D, *et al.* 2020. Signal Transduct Target Ther. 5:24. PubMed
120. Wei Z, *et al.* 2021. Nat Commun. 0.805555556. PubMed
121. Haque M, *et al.* 2021. STAR Protoc. 2:100264. PubMed
122. Baban B, *et al.* 2021. JCI Insight. 6:00. PubMed
123. Ouyang W, *et al.* 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
124. Kovacs SB, *et al.* 2021. STAR Protoc. 2:100244. PubMed
125. Kim SI, *et al.* 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
126. Sheng J, *et al.* 2021. eLife. 10:00. PubMed
127. Ni J, *et al.* 2020. Immunity. 52(6):1075-1087.e8. PubMed
128. Perner C, *et al.* 2020. Immunity. 53(5):1063-1077.e7. PubMed
129. Jiang L, *et al.* 2020. Cell. 183(5):1219-1233.e18. PubMed
130. Zhu XG, *et al.* 2020. Cell Metabolism. 33(1):211-221.e6. PubMed

131. Ringel AE, *et al.* 2020. Cell. 183(7):1848-1866.e26. PubMed
132. Xu W, *et al.* 2021. Immunity. 54(3):526-541.e7. PubMed
133. Han C, *et al.* 2021. Cell Reports. 34(6):108706. PubMed
134. Trefzer A, *et al.* 2021. Cell Reports. 34(6):108748. PubMed
135. Daneshmandi S, *et al.* 2021. Cell Reports. 34(10):108831. PubMed
136. Mitchell JE, *et al.* 2021. Cell Reports. 35(2):108966. PubMed
137. Harb H, *et al.* 2021. Immunity. 54(6):1186-1199.e7. PubMed
138. Souza COS, *et al.* 2021. iScience. 24(6):102548. PubMed
139. Xu C, *et al.* 2021. Cell Reports. 35(11):109235. PubMed
140. Marks KE, *et al.* 2021. Cell Reports. 35(13):109303. PubMed
141. Derada Troletti C, *et al.* 2021. Cell Reports. 35(9):109201. PubMed
142. Gary EN, *et al.* 2021. iScience. 24(7):102699. PubMed

RRID

AB_315403 (BioLegend Cat. No. 505809)
AB_315404 (BioLegend Cat. No. 505810)

Antigen Details

Structure

Cytokine; dimer; 40-80 kD (Mammalian)

Bioactivity

Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs

Cell Sources

$CD8^+$ and $CD4^+$ T cells, NK cells

Cell Targets

T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts

Receptors

IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)

Cell Type

Tregs

Biology Area

Cell Biology, Immunology, Neuroinflammation, Neuroscience

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, *et al.* Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, *et al.* 1992. *Curr. Opin. Immunol.* 4:321.
3. Farrar M, *et al.* 1993. *Annu. Rev. Immunol.* 11:571.
4. Gray P, *et al.* 1987. *Lymphokines* 13:151.

Regulation

Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone

Gene ID

15978

Related Protocols

Intracellular Cytokine Staining Protocol - Video

Intracellular Flow Cytometry Staining Protocol

Other Formats

APC anti-mouse IFN-γ, Biotin anti-mouse IFN-γ, FITC anti-mouse IFN-γ, PE anti-mouse IFN-γ, Purified anti-mouse IFN-γ, Alexa Fluor® 488 anti-mouse IFN-γ, Alexa Fluor® 647 anti-mouse IFN-γ, Pacific Blue™ anti-mouse IFN-γ, PerCP/Cyanine5.5 anti-mouse IFN-γ, PE/Cyanine7 anti-mouse IFN-γ, Brilliant Violet 421™ anti-mouse IFN-γ, Brilliant Violet 650™ anti-mouse IFN-γ, Ultra-LEAF™ Purified anti-mouse IFN-γ, Brilliant Violet 711™ anti-mouse IFN-γ, Brilliant Violet 785™ anti-mouse IFN-γ, Brilliant Violet 605™ anti-mouse IFN-γ, Brilliant Violet 510™ anti-mouse IFN-γ, Purified anti-mouse IFN-γ (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse IFN-γ, Alexa Fluor® 700 anti-mouse IFN-γ, APC/Cyanine7 anti-mouse IFN-γ, GoInVivo™ Purified anti-mouse IFN-γ, APC/Fire™ 750 anti-mouse IFN-γ, Spark NIR™ 685 anti-mouse IFN-γ

Product Data



PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587